Dec 20 2010
Import, sales and distribution of Phadia's allergy, asthma and autoimmunity diagnostics products, including ImmunoCAP and EliA, have been commercially approved by the Indian authorities.
Following official approval, Phadia will begin marketing a broad portfolio of diagnostic products to major commercial laboratories, hospitals and research institutes as well as to individual physicians.
"The Indian market is strategically important to Phadia with high economic growth and an expanding middle class demanding new and better healthcare solutions," says Jean Forcione, Chief Operating Officer, PhadiaAB.
With allergy prevalence estimated at over 30 per cent of the Indian population of 1.2bn people and the laboratory market expected to grow close to 20 per cent, Phadia sees substantial growth potential.
Phadia opened its own subsidiary in India in April 2010 and already works closely with several of the major commercial laboratories and major private hospital chains.
Survey unveils India's rising tide of metabolic diseases